| Literature DB >> 31319389 |
Jaffer A Ajani1, Thomas A D'Amico2, David J Bentrem3, Joseph Chao4, Carlos Corvera5, Prajnan Das1, Crystal S Denlinger6, Peter C Enzinger7, Paul Fanta8, Farhood Farjah9, Hans Gerdes10, Michael Gibson11, Robert E Glasgow12, James A Hayman13, Steven Hochwald14, Wayne L Hofstetter1, David H Ilson10, Dawn Jaroszewski15, Kimberly L Johung16, Rajesh N Keswani3, Lawrence R Kleinberg17, Stephen Leong18, Quan P Ly19, Kristina A Matkowskyj20, Michael McNamara21, Mary F Mulcahy3, Ravi K Paluri22, Haeseong Park23, Kyle A Perry24, Jose Pimiento25, George A Poultsides26, Robert Roses27, Vivian E Strong10, Georgia Wiesner11, Christopher G Willett2, Cameron D Wright28, Nicole R McMillian29, Lenora A Pluchino29.
Abstract
Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.Entities:
Year: 2019 PMID： 31319389 DOI： 10.6004/jnccn.2019.0033
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908